India's CDMO Sector Poised for Growth as Pharma Diversifies Beyond China

The global pharmaceutical supply chain is undergoing a structural realignment as multinational drugmakers seek to reduce their dependence on Chinese manufacturing. As regulatory scrutiny intensifies around Chinese giants like WuXi AppTec, Indian Contract Development and Manufacturing Organisations (CDMOs) are emerging as the primary beneficiaries of this strategic shift.

India Emerges as the Preferred Alternative to China

The movement away from China-centric manufacturing is not a sudden reaction to recent geopolitical developments but a trend that began nearly two years ago. According to Sivaramakrishnan Chittor, CFO of Sai Life Sciences, global pharmaceutical companies have already initiated deep conversations with Indian players to diversify their footprints.

The inclusion of certain entities in regulatory lists has provided much-needed clarity for global firms looking to de-risk their supply chains. Indian CDMOs are responding to this demand by aggressively scaling up operations and committing significant capital expenditure (capex) to ensure they can meet the requirements of global innovators.

Sai Life Sciences: Strategic Expansion and Revenue Shifts

Sai Life Sciences is positioning itself at the forefront of this transition, currently working with 19 of the top 25 global pharmaceutical companies. The company's data reveals a significant shift in its revenue composition: over the last four years, the contribution from large global pharmaceutical companies has nearly doubled, rising from 28% to 49% of its total revenue.

To capitalize on these opportunities, Sai Life Sciences has announced a substantial expansion plan. The company intends to invest between ₹1,100 crore and ₹1,300 crore in capacity expansion by FY27. This investment will be financed through a combination of internal accruals and debt, maintaining a healthy balance sheet given their current minimal debt position.

From Clinical Supplies to Commercial-Scale Manufacturing

A critical evolution in the Indian CDMO landscape is the shift in the nature of work being outsourced. Historically, many global firms used India primarily for clinical trial supplies. However, there is a growing trend toward utilizing Indian facilities for commercial-scale manufacturing.

Sai Life Sciences has noted a significant increase in its late-stage development pipeline. The number of Phase III and pre-registration molecules has grown from six to eleven over the past year. This increase in Phase III molecules is a fundamental indicator that global pharma companies now view India as a reliable partner for large-scale, commercial-stage production rather than just early-stage research.

While the opportunity is immense, industry leaders caution that the transition will not yield immediate quarterly results. Because pharmaceutical manufacturing is heavily regulated, moving a product from one manufacturer to another requires rigorous approvals and lengthy transfer timelines.

Despite these temporal challenges, Sai Life Sciences has maintained its revenue growth guidance of a 15-20% CAGR. The company expects its performance to strengthen in the latter half of the fiscal year as new production capacities come online and order visibility improves.

Key Takeaways

  • Supply Chain Diversification: Global pharma companies are actively moving away from China, positioning Indian CDMOs as the most viable long-term alternatives.
  • Shift to Commercial Scale: Indian manufacturers are moving up the value chain, transitioning from providing clinical supplies to handling large-scale commercial manufacturing.
  • Aggressive Capex: Major players like Sai Life Sciences are investing up to ₹1,300 crore in capacity expansion to meet the rising global demand.